$Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma$
QR Code

QR Code

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma

Sam Mayes,1 Adam Gibb,1 Tim Illidge1,21The Christie Hospital NHS Foundation, Wilmslow Road, 2School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Health Sciences Centre, UKAbstract: Treatment of primary refractory and relapsed classical Hodgkin lymphoma remains chall...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Illidge T, Gibb A, Mayes S
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2012
Sujets:	Diseases of the blood and blood-forming organs RC633-647.5
Accès en ligne:	https://doaj.org/article/779540bde3854435a910b61767fd764a
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
par: Lai C, et autres
Publié: (2019)

TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
par: Ebru Pekgüç, et autres
Publié: (2021)

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
par: Gupta VA, et autres
Publié: (2013)

MEDICAL TREATMENT IN HODGKIN LYMPHOMA
par: Nilgun Kurucu
Publié: (2021)

ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
par: Sanda Buruiana, et autres
Publié: (2021)

Intrasinusoidal Hodgkin Lymphoma; A Mimic of Anaplastic Large Cell Lymphoma
par: John R. Krause, et autres
Publié: (2021)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
par: Eko A. Pangarsa, et autres
Publié: (2021)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
par: Julio Delgado, et autres
Publié: (2021)

MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
par: Lim EL, et autres
Publié: (2013)

Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
par: McKinney MS, et autres
Publié: (2014)

Reduced intensity treatment in early-stage Hodgkin&rsquo;s lymphoma
par: Armitage JO, et autres
Publié: (2011)

PROGNOSIS FACTORS IN AGGRESSIVE NON-HODGKIN LYMPHOMAS WITH PRIMARY INVOLVEMENT OF THE SPLEEN
par: Larisa Musteata, et autres
Publié: (2021)

mTOR inhibitor in the treatment of Hodgkin&rsquo;s lymphoma: a case report
par: Provencio M., et autres
Publié: (2011)

CLINICAL CHARACTERISTICS, AND SURVIVAL RATE OF ELDERLY PATIENTS WITH NON-HODGKIN'S LYMPHOMAS WITH PRIMARY INVOLVEMENT OF PERIPHERAL LYMPH NODES
par: Tomacinschii Victor, et autres
Publié: (2021)

Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
par: Giancarlo Fatobene, et autres
Publié: (2021)

Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
par: Lapuz C, et autres
Publié: (2018)

Bone marrow necrosis in a patient with advanced Hodgkin's lymphoma after G-CSF and Plerixafor treatment during harvesting for autologous bone marrow transplantation: is it possible?
par: Najmaddin Khoshnaw, et autres
Publié: (2021)

The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
par: Kaufman GP, et autres
Publié: (2014)

Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
par: Farina F, et autres
Publié: (2014)

Advances in the diagnosis and management of lymphoma
par: Matasar MJ, et autres
Publié: (2012)

THE SMALLEST PRIMARY BONE LYMPHOMA
par: Fatma Burçin KURTİPEK, et autres
Publié: (2021)

MYC as therapeutic target in leukemia and lymphoma
par: Cortiguera MG, et autres
Publié: (2015)

IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT
par: Hana Qasim
Publié: (2021)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
par: Liu YC, et autres
Publié: (2014)

Peripheral T cell lymphoma: clinical utility of romidepsin
par: Sawey K, et autres
Publié: (2012)

Preserving fertility in young patients with lymphoma: an overview
par: Patel B, et autres
Publié: (2014)

MicroRNAs as B-cell lymphoma biomarkers
par: Manterola L, et autres
Publié: (2015)

Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma
par: Yoshimitsu M, et autres
Publié: (2014)

THREE CASES WITH BURKITT LYMPHOMA PRESENTING WITH CHOLESTASIS
par: Fatma Tuba YILDIRIM, et autres
Publié: (2021)

CASE REPORT: FOLLICULAR LYMPHOMA PRESENTED WITH CHYLOTHORAX
par: Senem MARAL, et autres
Publié: (2021)

A CASE OF REFRACTORY IMMUNE THROMBOCYTOPENIA APPLIED WITH AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION
par: Mine KARADENIZ, et autres
Publié: (2021)

Emerging role of SOX11 in mantle cell lymphoma
par: Kuci V, et autres
Publié: (2015)

A CASE OF MULTI REGIONAL PRIMARY MUSCLE LYMPHOMA
par: Beyza OLUK, et autres
Publié: (2021)

A RARE CASE: POSTTRANSPLANT NK/T CELL LYMPHOMA
par: Pınar Tığlıoğlu, et autres
Publié: (2021)

Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
par: Thomas X
Publié: (2014)

Immune targeted therapy for diffuse large B cell lymphoma
par: Yaxin Zheng, et autres
Publié: (2021)

Emerging targets in human lymphoma: targeting the MYD88 mutation
par: Wang JQ, et autres
Publié: (2013)

BURKITT LYMPHOMA PRESENTING WITH EYE AND KIDNEY INVOLVEMENT: CASE REPORT
par: Aslı Turgutoğlu Yılmaz, et autres
Publié: (2021)

UPSHOTS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: ANALYSIS OF T-CELL BRAZIL PROJECT
par: Carlos CHIATTONE, et autres
Publié: (2021)

Monomorphic epitheliotropic intestinal T-cell lymphoma of the duodenum: an aggressive disease
par: Ganesh Kasinathan
Publié: (2021)